Expert Shares Main Takeaway From Phase III TAGS Trial in Patients With Gastric/GEJ Cancer

February 1, 2019
David H. Ilson, MD, PhD

David H. Ilson, MD, PhD, discusses the main takeaway from the data for phase III TAGS trial reported at the 2019 Gastrointestinal Cancers Symposium.

David H. Ilson, MD, PhD, attending physician and professor of medicine at Memorial Sloan Kettering Cancer Center, discusses the main takeaway from the data for the phase III TAGS trial reported at the 2019 Gastrointestinal Cancers Symposium.

Treatment with TAS-102 (trifluridine/tipiracil; FTD/TPI; Lonsurf) modestly improved progression-free survival and overall survival in patients with refractory gastric or gastroesophageal junction (GEJ) cancer. However, Ilson says this is more of a stabilizing drug since there weren’t really any responses.

Quality of life data in the original trial also showed a slow decline in performance status with TAS-102 compared to placebo. Ilson says this will likely be a good option for patients with refractory disease who do not have other treatment options.

See more from this trial.